Clinical Trial Update: Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating bevacizumab plus a modified FOLFOX6 regimen as salvage therapy for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED